This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cell Therapeutics Lavishes Free Stock on Execs: BioBuzz

SEATTLE ( TheStreet) -- Christmas and Hanukah came early this year for executives and directors at Cell Therapeutics (CTIC - Get Report).

On Nov. 10, the company gave nearly 10 million shares in free stock grants to senior management and directors. The largest single award -- almost 3 million shares -- went to CEO Jim Bianco, according to filings made with the Securities and Exchange Commission.

The granting of free stock (the cost basis for the shares was zero) is part of the company's "long-term equity and retention" program, said Cell Therapeutics spokesman Dan Eramian, in an email statement.

With largesse like this, it's a wonder that any of Cell Therapeutics' executives would even think about leaving!

At Friday's close of 98 cents, Cell Therapeutics shares are up 600% this year, but the stock is down 50% from its June high due to a number of setbacks and disappointments related to the company's drug pipeline. In August, the FDA refused to grant priority, six-month review to its lymphoma drug pixantrone, while Cell Therapeutics, in September, withdrew its European approval application for the lung cancer drug Opaxio. The company is also still struggling with cash and debt issues.

Bianco benefited the most from the new stock grants. He was awarded 2.9 million free shares of Cell Therapeutics stock. After accounting for stock sold to cover taxes, Bianco's take amounted to more than $1.8 million, based on the stock's Nov. 10 closing price.

In addition to Bianco, four other top executives were awarded similar free stock grants, as were all six of the company's outside directors.

Poniard Cancer Drug Fails Pivotal Study

(At 8:01 AM ET)

Poniard Pharmaceuticals' (PARD) cancer drug picoplatin failed to significantly prolong survival in patients with advanced small cell lung cancer, according to results of a pivotal study disclosed Monday.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CTIC $1.82 0.00%
PARD $0.10 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs